Tech Company Financing Transactions
AdvanCell Funding Round
On 7/15/2026, AdvanCell secured $315 million in Series D funding from Ally Bridge Group, Alpha Wave Ventures and Abingworth.
Transaction Overview
Company Name
Announced On
7/15/2026
Transaction Type
Venture Equity
Amount
$315,000,000
Round
Series D
Investors
Ally Bridge Group (Lead Investor)
Alpha Wave Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance ADVC001, its novel Lead-212 PSMA-targeted radioligand therapy for metastatic prostate cancer toward Phase 3 development, expand vertically integrated radiopharmaceutical platform and manufacturing infrastructure, and accelerate its growing pipeline of targeted alpha therapies
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Level 7, Macquarie House, 167 Macquarie St,
Sydney, NSW, 2000
AU
Sydney, NSW, 2000
AU
Phone
Undisclosed
Website
Email Address
Overview
AdvanCell is a radiopharmaceutical company developing next-generation cancer treatments. AdvanCell's targeted alpha therapies are powered by a platform technology -- a world-first alpha isotope generator which addresses the greatest unmet need in targeted alpha therapy -- the reliable and scalable supply of isotope.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Bill Ferris
Chief Executive Officer
Andrew Adamovich
Chief Technical Officer
Simon Puttick
Browse more venture capital transactions:
Prev: 7/15/2026: Rime Labs venture capital transaction
Next: 7/16/2026: Fave venture capital transaction
Share this article
Where The Data Comes From
We record tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs